The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer
Key result
SGLT2i use in older diabetics receiving anthracyclines is linked to ~100% lower HF hospitalization risk.
- HR 0
- P<0.001
- n=933
Why the study?
SGLT2is are hypothesized to reduce anthracycline-associated cardiotoxicity, but their association with cardiovascular disease after anthracycline-containing chemotherapy required evaluation.
Do SGLT2 inhibitors reduce the risk of heart failure hospitalization, incident heart failure, or cardiovascular disease in older patients with diabetes receiving anthracycline chemotherapy?
Population
933 patients >65 years of age with treated diabetes and no prior HF receiving anthracyclines
Comparison
SGLT2i-treated vs unexposed controls
Design
Population-based cohort study using administrative data sets with propensity score weighting
Follow-up
Median 1.6 years
Authors
Discussion
Loading...
Member takes
Implication
Supports potential SGLT2i cardioprotection in anthracycline-treated diabetes; leaves open confirmation by randomized trials before practice change.
Study Design
Type
Cohort (n=933)
Structured PICO
Do SGLT2 inhibitors reduce the risk of heart failure hospitalization, incident heart failure, or cardiovascular disease in older patients with diabetes receiving anthracycline chemotherapy?
P
Population
933 patients >65 years of age with treated diabetes and no prior heart failure who received anthracycline-containing chemotherapy, median age 71.0 years, 62.2% female.
I
Intervention
Sodium-glucose cotransporter 2 inhibitors (SGLT2is)
C
Comparator
Unexposed controls (no SGLT2i), weighted using propensity scores (average treatment effects for the treated weights)
O
Outcome
Hospitalization for heart failure, incident heart failure diagnoses (in- or out-of-hospital), and documentation of any cardiovascular disease in future hospitalizationshard clinical
Main Result
Effect estimate: HR 0
Absolute Event Rate: 0% vs 3.7%
p-value: p=<0.001
In older patients with diabetes receiving anthracycline chemotherapy, SGLT2 inhibitor use was associated with a significantly lower risk of heart failure hospitalization, suggesting a potential cardioprotective role in cardio-oncology.
Cite This Study
Abdel‐Qadir et al. (2023) conducted a cohort in Treated diabetes and no prior heart failure receiving anthracyclines (n=933). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) vs. Unexposed controls was evaluated on Hospitalization for HF (HR 0, p=<0.001). SGLT2i exposure in older patients with diabetes receiving anthracyclines was associated with a lower risk of heart failure hospitalization (HR 0; P<0.001) compared to unexposed controls.